Merck & Co.
AWARDS
NEWS
Under the agreement, Merck can use Synthekine’s surrogate cytokine agonist platform to discover, develop, and sell new cytokine-based treatments for up to two cytokine targets.
The decision came after Avoro Capital Advisors, which owns a 7% stake in Acceleron, posted its objections to the deal.
Yet another busy week for clinical trial news. Here’s a look.
Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round. The company focuses on developing treatments for celiac disease and other immune-related conditions.
Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.
The two Phase III studies are part of the ILLUMINATE clinical trial, which looks into the action of doravirine/islatravir (DOR/ISL) on HIV-1.
JOBS
IN THE PRESS